Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABI Prior to CD19 CAR-T in Relapsed/Refractory Large B Cell Lymphoma
NCT06104592Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Moffitt Cancer Center. Started Nov 2023; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06104592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104592.